J.Pharma · Weight Loss · Research Peptide

GLP-2 (GLP-2)

Dual GIP/GLP-1 receptor agonist. Two complementary incretin pathways in a single compound — available in 10mg and 20mg.

99%+ Purity Third-Party Tested US-Based Free Shipping COA Available
🧪 99%+ Purity Lab Certified
🇺🇸 US-Based Fast Dispatch
📦 Discreet Plain Packaging
🚚 Free Shipping All Orders
📋 COA Available on Request

About GLP-2 (GLP-2)

GLP-2 is the research designation for GLP-2, a dual receptor agonist that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. By engaging two distinct incretin pathways, it represents a mechanistic evolution from single-receptor GLP-1 agonists.

GIP receptor activation influences insulin secretion in a glucose-dependent manner and may modulate adipose tissue function and energy balance. GLP-1 receptor activation reduces gastric emptying, suppresses glucagon secretion, and decreases appetite signaling through central and peripheral mechanisms. The dual agonism creates complementary and potentially synergistic effects that have made GLP-2 a subject of significant research interest in metabolic science.

Purity
≥99%
HPLC-UV verified
Identity
LC-MS Confirmed
Mass spectrometry
Form
Lyophilized Powder
Requires reconstitution
Storage
Lyophilized: Room temp or 2–8°C
After reconstitution: 2–8°C
Available Sizes
10mg
Lyophilized powder · 99%+ purity
$60
Order →
20mg
Lyophilized powder · 99%+ purity
$75
Order →
🧪 Reconstitution
Reconstitute with Bacteriostatic Water. GLP-2 is particularly prone to foaming — add BAC Water very slowly angled down the vial wall. Do not shake. Swirl gently. Standard protocol: 1 mL BAC Water per 10mg vial (10 mg/mL); 2 mL per 20mg vial (10 mg/mL). If foaming occurs, allow the vial to rest refrigerated for 10–15 minutes before use. Visit our full Reconstitution Guide and Dosing Calculator for detailed instructions.

Research Applications

GLP-2 (GLP-2) is used in research investigating dual incretin receptor pathway modulation, insulin sensitivity, appetite regulation, and body composition. Research applications include comparative studies between mono- and dual-receptor agonists, investigations of GIP vs. GLP-1 contribution to metabolic outcomes, and studies of gastric motility under dual-receptor conditions.

For research use only. All products sold by J.Pharma are intended strictly for in vitro laboratory research. Not for human or veterinary use. Not FDA approved for any therapeutic purpose.

Common Questions

What is GLP-2?
GLP-2 is the research name for GLP-2 — a dual GIP/GLP-1 receptor agonist. It differs from GLP-1 monoagonists by additionally targeting the GIP receptor, which adds a second incretin pathway to the mechanism.
What sizes is GLP-2 available in?
J.Pharma carries GLP-2 (GLP-2) in 10mg and 20mg vials.
How do I reconstitute GLP-2?
Use Bacteriostatic Water. GLP-2 is prone to foaming — add BAC Water very slowly down the vial wall. For 10mg: add 1 mL BAC Water (10 mg/mL). For 20mg: add 2 mL BAC Water (10 mg/mL). Swirl gently, never shake. If foaming occurs, rest in refrigerator 10–15 minutes.
What is the difference between GLP-2 and GLP-3?
GLP-2 (GLP-2) targets two receptors: GIP and GLP-1. GLP-3 (GLP-3) targets three: GIP, GLP-1, and glucagon. The additional glucagon receptor component in GLP-3 is believed to further increase energy expenditure.
Is GLP-2 the same as semaglutide?
No. Semaglutide is a GLP-1 monoagonist — it targets only the GLP-1 receptor. GLP-2 (GLP-2) targets both GIP and GLP-1 receptors, making it mechanistically distinct.

Related Compounds

Regulatory Notice

None of the statements on this website have been reviewed or approved by the U.S. Food and Drug Administration. J.Pharma products are not intended to diagnose, treat, cure, or prevent any disease or medical condition. All products are sold strictly for in vitro laboratory research purposes. They are not for human or animal use of any kind. DiPerna Services, LLC d/b/a J.Pharma is not a compounding pharmacy or outsourcing facility as defined under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.